• Cardiovascular disease in women depending on hormonal continuum: prevention and treatment strategies 
To content

Cardiovascular disease in women depending on hormonal continuum: prevention and treatment strategies 

HEALTH OF WOMAN. 2016.4(110):43–47; doi 10.15574/HW.2016.110.43 

Cardiovascular disease in women depending on hormonal continuum: prevention and treatment strategies 

Davidova I. V., Mymrenko S. M., Perepelchenko N. A., Konoplyanik L. I.

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev 

To date, no doubt the close relationship between the functioning of the cardiovascular and reproductive systems in women. For more successful solution of the problem of cardiovascular diseases in women required a multidisciplinary approach and integration efforts as cardiologists and gynecologists.

The term «hormonal continuum of women’s health» includes the evaluation of development risk factors, diagnosis, prevention and treatment strategy for CVD depending on the hormonal status and the condition of the sexual sphere of women in different periods of her life.

One of the most characteristic psychological features of patients in menopausal period with concomitant hypertensive disease is high levels of anxiety, and negative emotional state affects the course of disease, effectiveness of treatment, quality of life of patients. The presence of anxiety and depression increases the risk of cardiovascular diseases and their complications.

Therefore, effective therapy of patients with hypertension include not only reduction of blood pressure to target levels, but in some cases the treatment of anxiety disorders and depression.

Correction of «early» symptoms of climacteric disorders with Alesana can play a significant role in the prevention of cardiovascular diseases.

Key words: cardiovascular disease, hormonal continuum of hypertension in women, psychosomatic disorders, treatment.


1. Ayvazyan TA. 2002. Osnovnyie printsipyi psihokorrektsii pri gipertonicheskoy bolezni. Atmosfera. Kardiologiya 1(2).

2. Andruschenko KV. 2003. Byit nastoyaschey zhenschinoy vsegda. Zdorov’ya Ukraini 19(80):27.

3. Bobrov VO, Davydova IV, Ventskivskyi BM. 2000. Arterialna hipertenziia u zhinok v period menopauzy: osoblyvosti diahnostyky, dyferentsiiovane likuvannia. Metodychni rekomendatsii. K:25.

4. Zueva NA. 2004. Osnovnyie printsipyi lecheniya arterialnoy gipertenzii pri metabolicheskom sindrome. Zdorov’ya UkraYini 6:12.

5. Morozov PV. 2005. Terapiya depressii i trevozhnyih rasstroystv v sovremennoy psihiatrii. Consilium medicum 3.

6. Pykovodstvo po klimakteriyu. Pod red. VP Smetrik, VI Kulakova. M, Meditsinskoe informatsionnoe agentstvo. 2001:685.

7. Svischenko EP, Kovalenko VN. 2001. Arterialnaya gipertenziya. Prakticheskoe rukovodstvo. K, MORION:527.

8. Strokovskaya N. 2004. Menopauza: sdelay pauzu – s'esh gormon. Segodnya 38:3.

9. Amit Shah J et al. 2014, Jun. Sex and Age Differences in the Association of Depression With Obstructive Coronary Artery Disease and Adverse Cardiovascular Events. J Am Heart Assoc. 3(3):e000741. http://dx.doi.org/10.1161/JAHA.113.000741; PMid:24943475 PMCid:PMC4309058

10. Burkman RT. 2001. The hormone continuum accrual of women’s health benefits Am J Obstet Gynecol 185(2 Suppi) Sl-3.

11. Dahlof B, Lindholm LN, Hansson L еt al. 1991. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 338:1281–1285. http://dx.doi.org/10.1016/0140-6736(91)92589-T

12. Grodstein F, Clarkson TB, Manson JE. 2003. Understanding the divergent data on postmenopausal hormone therapy. N Engi J Med. 348;7:645–650. http://dx.doi.org/10.1056/NEJMsb022365; PMid:12584376

13. Guidelines Committee. 2013 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2013. 21:1011–1053.

14. Jiang С, Poole-Wilson PA. 2002. Effects of 17(3 oestradiol on contraction, Ca2+ in guinea-pig isolated cardiac myocites. Br J Pharmacol. 106:739–45. http://dx.doi.org/10.1111/j.1476-5381.1992.tb14403.x

15. Lirm ES, Kaumtz AM, Schnare S, Taylor M. 2001. The hormone continuum accrual of women’s health benefits. Int J Fertil Womens Med 46(2):60–72.

16. Lobo RA. 2001, Dec. Menopauza: suchasni terapevtichny pidhodi. Meditcyna svitu ХІ;6:295–309.

17. Meg L, Chen D, Yang Y et al. 2012. Depression increases risk of hypertension incidence: a meta-analyses of prospective cohort study. Journal of Hypertension 30:842–851. http://dx.doi.org/10.1097/HJH.0b013e32835080b7; PMid:22343537

18. Sattar N, Greer IA. 2002. Pregnancy complications and maternal cardiovascular risk opportunities for intervention and screening. Br Med J. 325:157–160. http://dx.doi.org/10.1136/bmj.325.7356.157

19. Soranno D, Prasad V, Oberfield DR, Greco A, Sivaraman N, Drucker W. 1999. Hypertension and virilization caused by unique dexoxycorticosterone and androgen-secreting adrenal adenoma. J Pediatr Endocrinol Metab. 12:215–220. http://dx.doi.org/10.1515/JPEM.1999.12.2.215; PMid:10392370

20. Taavoni S, Ekbatani N, Kashaniyan M, Haghani H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial.

21. Talbott E, Guzick D, Clenci A, Berga S, Detre K, Weimer K, Kuller L. 1995. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 15:821–826. http://dx.doi.org/10.1161/01.ATV.15.7.821; PMid:7600112

22. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. 2002. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia-a randomized, double-blind, comparative clinical study.

23. Wilson BJ, Watson MS, Prescot GJ et al. 2003. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life results from cohort study. Br Med J. 326:845–849. http://dx.doi.org/10.1136/bmj.326.7394.845; PMid:12702615 PMCid:PMC153466